NCT01069627View on ClinicalTrials.gov

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Malignant Melanoma
Interventions
DRUG

bevacizumab [Avastin]

15 mg/kg intravenously on day 1 of every 3 week cycle

DRUG

fotemustine

100 mg/m² intravenously on Days 1, 8, and 15, followed by 4 weeks of rest, then every 21 days up to 4 to 6 cycles

Trial Locations (4)

10126

Torino

16132

Genova

20133

Milan

50100

Florence

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01069627 - A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter